Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial

被引:26
作者
Hollebecque, A. [1 ]
Borad, M. [2 ]
Goyal, L. [3 ]
Schram, A. [4 ]
Park, J. O. [5 ]
Cassier, P. A. [6 ]
Kamath, S. D. [7 ]
Meng, D. T. Wai [8 ]
Dotan, E. [9 ]
Kim, R. [10 ]
Sahai, V. [11 ]
Oh, D-Y. [12 ]
Liao, C-Y. [13 ]
Millward, M. [14 ,15 ]
Perez, D. Roda [16 ]
Ferte, C. [17 ]
Blakesley, R. [18 ]
Wolf, B. [19 ]
Subbiah, V. [20 ]
Kelley, R. K. [21 ]
机构
[1] Inst Gustave Roussy, DITEP, Villejuif, France
[2] Mayo Clin, Dept Oncol, Canc Ctr, Scottsdale, AZ USA
[3] Massachusetts Gen Hosp, Med Oncol, Boston, MA USA
[4] MSKCC Mem Sloan Kettering Canc Ctr, Med Dept, New York, NY USA
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Med Oncol, Seoul, South Korea
[6] Ctr Leon Berard, Med Oncol Dept, Lyon, France
[7] Cleveland Clin, Taussig Canc Ctr, Gastrointestinal Oncol, Cleveland, OH USA
[8] Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore
[9] Fox Chase Canc Ctr, Main Campus, Philadelphia, PA USA
[10] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, GI Oncol Dept, Tampa, FL USA
[11] Univ Michigan, Michigan Med, Med Oncol, Ann Arbor, MI USA
[12] Seoul Natl Univ Hosp, Internal Med Dept, Seoul, South Korea
[13] Univ Chicago, Med Hematol Oncol Sect, Dept Med Sect Hematol Oncol, Chicago, IL USA
[14] Linear Clin Res, Sch Med, Perth, WA, Australia
[15] Univ Western Australia, Perth, WA, Australia
[16] Hosp Clin Univ Valencia, Oncol Dept, Valencia, Spain
[17] Relay Therapeut Inc, Sci Commun, Cambridge, MA USA
[18] Relay Therapeut Inc, Biostat, Cambridge, MA USA
[19] Relay Therapeut Inc, Precis Med, Cambridge, MA USA
[20] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX USA
[21] UCSF Helen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
关键词
D O I
10.1016/j.annonc.2022.08.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LBA12
引用
收藏
页码:S1381 / S1381
页数:1
相关论文
empty
未找到相关数据